CMA’s Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals: Federal levers to address unintended consequences of prescription pharmaceuticals and support public health, quality care, and patient safety
https://policybase.cma.ca/link/policy11125

POLICY TYPE: Parliamentary submission
DATE: 2014-03-26
TOPICS: Pharmaceuticals, prescribing, cannabis, drugs

Documents

Child's Submission to the Senate Committee on Social Affairs, Science and Technology as part of its study on prescription pharmaceuticals

March 26, 2014

Submitted For:

Less Tax to be Burnt

Published on: Canadian Medical Association

For permission to reprint, contact policybase.ca/pubs/permissions.html

(622) 492-8000, 1-800-668-0488, info@policybase.ca

CMA Policybase - Canadian Medical Association
Consultation on the prescription drug list: Naloxone
https://policybase.cma.ca/link/policy11847

POLICY TYPE Response to consultation

DATE 2016-03-19

TOPICS Pharmaceuticals, prescribing, cannabis, drugs

Documents
Harms associated with opioids and other psychoactive prescription drugs
https://policybase.cma.ca/link/policy11535

POLICY TYPE
Policy document

DATE
2015-05-30

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

HARMS ASSOCIATED WITH OPIOIDS AND OTHER PSYCHOACTIVE PRESCRIPTION DRUGS

Preamble
The harms associated with psychoactive prescription medications (including opioids) have been acknowledged and addressed by national and international bodies, including the World Health Organization (WHO). In Canada, the use of opioids has increased significantly in recent years, leading to concerns about their potential for misuse and abuse, as well as their potential to cause significant harm. The Canadian Medical Association (CMA) has been actively involved in the development of policies and guidelines to help address these concerns.

Policy
The CMA believes that the use of opioids and other psychoactive prescription drugs should be carefully controlled and monitored to ensure their safe and appropriate use. This includes the development of guidelines for prescribers to help them identify patients at risk of misuse or abuse and to provide appropriate care and support.

Recommendations
1. The CMA recommends that health care professionals be provided with evidence-based guidelines to help them identify patients at risk of misuse or abuse of opioids and other psychoactive prescription drugs.
2. The CMA recommends that health care professionals be provided with education and training on the safe and appropriate use of opioids and other psychoactive prescription drugs.
3. The CMA recommends that health care professionals be provided with resources to help them support patients who are experiencing harm or who may be at risk of harm from the use of opioids and other psychoactive prescription drugs.

Conclusion
The CMA is committed to working with other stakeholders to address the harms associated with opioids and other psychoactive prescription drugs. This includes the development of policies and guidelines to help ensure their safe and appropriate use, as well as the provision of education and training to health care professionals.

For more information, please visit the CMA website at: www.cma.ca

The Canadian Medical Association (CMA) is the national organization representing medically trained physicians in Canada. The CMA represents the interests of more than 60,000 physicians across the country.

Additional Resources
- Canadian Pharmacists Association
- Canadian Addiction Society
- Canadian Pain Society
Health Canada consultation on Canadian drugs and substances strategy
https://policybase.cma.ca/link/policy14017

POLICY TYPE  Response to consultation
DATE  2018-12-04
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Health Canada consultation on regulatory amendments regarding tramadol

https://policybase.cma.ca/link/policy13927

POLICY TYPE           Response to consultation
DATE                   2018-08-14
TOPICS                 Pharmaceuticals, prescribing, cannabis, drugs

Documents

HEALTH CANADA CONSULTATION ON REGULATORY AMENDMENTS REGARDING TRAMADOL

August 14, 2018
Health Canada consultation on restriction of marketing and advertising of opioids
https://policybase.cma.ca/link/policy13921

POLICY TYPE  Response to consultation
DATE  2018-07-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA response:

HEALTH CANADA CONSULTATION ON RESTRICTION OF MARKETING AND ADVERTISING OF OPIOIDS

Jun 18, 2018
The Need for a National Strategy to Address Abuse and Misuse of Prescription Drugs in Canada: Canadian Medical Association Submission to the House of Commons Standing Committee on Health

https://policybase.cma.ca/link/policy11035

POLICY TYPE
Parliamentary submission

DATE
2013-11-27

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

POLICY TYPE  Response to consultation
DATE  2017-11-7
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

https://policybase.cma.ca/link/policy13932

POLICY TYPE
Policy endorsement

DATE
2018-10-31

TOPICS
Population health, health equity, public health

Documents

Open letter to Ontario Minister of Health about the newly proposed “Consumption and Treatment Services” model

October 31, 2018

Ron Hume, M.D., FRCPC
Minister of Health

We write on behalf of the Canadian Medical Association (CMA) as the lead organization of 60 medical and regulatory bodies, in response to a Public Health Announcement from the Hon. Steven Del Duca, MPP, Minister of Health and Long-Term Care, that Consumption and Treatment Services (C&TS) are to be rolled out in Ontario. C&TS offer a clear example of the public health sector’s commitment to implementing the lessons learned from evidence-based harm reduction strategies. CMA endorses rolling out C&TS in all jurisdictions, in tandem with harm reduction policies and measures, to help the most vulnerable populations reduce their health risks.

As noted in a recent Public Health Announcement on the C&TS, “we recognize that many people continue to use cannabis in way that is not consistent with the health and safety of themselves and others.” C&TS’ goal is to provide a safe, regulated and controlled environment for consumption and treatment of cannabis, to reduce the risks of overdose, infections, drug interactions, as well as violence and property damage. ""C&TS” are also intended to support patients currently using cannabis for medical purposes, improve access to essential life-saving medicines, reduce the risk of respiratory infections, and address concerns related to the safety of children and pets in the home.

While we welcome the Minister’s commitment to continue moving forward with C&TS, we have concerns about the public health risks associated with the implementation of C&TS. We are concerned about the potential for an increase in the consumption of cannabis and its derivatives, including the use of cannabis dermapharmaceuticals, such as edible cannabis. In addition, we are concerned about the potential for an increase in the use of cannabis among individuals who are currently not using it. We also have concerns about the potential for an increase in the use of cannabis among individuals who are currently not using it. We encourage the Ontario Government to continue to monitor the impact of C&TS and to be prepared to adjust the program as needed.

We are also concerned about the potential for an increase in the use of cannabis among individuals who are currently not using it. We encourage the Ontario Government to continue to monitor the impact of C&TS and to be prepared to adjust the program as needed.

We look forward to continuing to engage with the Ontario Government on this important issue.

Yours sincerely,

Ron Hume, M.D., FRCPC

Policies, Ethics, and Professional Standards

Canadian Medical Association
Proposed amendments to the marihuana for medical purposes regulations
https://policybase.cma.ca/link/policy11293

POLICY TYPE  Response to consultation
DATE  2014-07-11
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Review of Controlled Drugs and Substances Act: Canadian Medical Association submission to Health Canada in response to the consultation on the Controlled Drugs and Substances Act and its regulations

https://policybase.cma.ca/link/policy11114

**POLICY TYPE**  
Response to consultation

**DATE**  
2014-03-17

**TOPICS**  
Pharmaceuticals, prescribing, cannabis, drugs

**Documents**
Statement to the House of Commons Committee on Health addressing the opioid crisis in Canada
https://policybase.cma.ca/link/policy13936

POLICY TYPE  Parliamentary submission
DATE      2016-10-18
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health
Health care and patient safety

Documents
Support life-saving supervised consumption and overdose prevention sites: open letter to Premier Doug Ford and Health Minister Christine Elliott
https://policybase.cma.ca/link/policy13931

POLICY TYPE  Policy endorsement
DATE  2018-08-30
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents

[Image]